This is a preview of subscription content, log in via an institution to check access.
Data availability
Data available upon request to the corresponding author.
References
Rovin BH, Adler SG, Barratt J, KDIGO et al (2021) Clinical practice guideline for the management of glomerular diseases. Kidney Int Suppl 2021:2021. https://doi.org/10.1016/j.kint.2021.05.021
Manno C, Torres DD, Rossini M, Pesce F, Schena FP (2009) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24(12):3694–3701. https://doi.org/10.1093/ndt/gfp356
Pozzi C, Bolasco PG, Fogazzi GB et al (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet (London, England) 353(9156):883–887
Lv J, Wong MG, Hladunewich MA et al (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING Randomized Clinical Trial. JAMA 327(19):1888. https://doi.org/10.1001/JAMA.2022.5368
Tang SCW, Tang AWC, Wong SSH, Leung JCK, Ho YW, Lai KN (2010) Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77(6):543–549. https://doi.org/10.1038/ki.2009.499
Tang S, Leung JCK, Chan LYY et al (2005) Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 68(2):802–812. https://doi.org/10.1111/j.1523-1755.2005.00460.x
Hou JH, Le WB, Chen N et al (2017) Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 69(6):788–795. https://doi.org/10.1053/j.ajkd.2016.11.027
Hogg RJ, Bay RC, Jennette JC et al (2015) Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 66(5):783–791. https://doi.org/10.1053/j.ajkd.2015.06.013
Maes BD, Oyen R, Claes K et al. (2004) Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. In: Kidney International, Vol 65. Blackwell Publishing Inc. pp 1842–1849. https://doi.org/10.1111/j.1523-1755.2004.00588.x
Funding
No funding was required for the present study.
Author information
Authors and Affiliations
Contributions
FF conceived the study; FF, MD, MV, CP, SG, GL, ML collected the data; FF, MD and GA analyzed the data; FF, MD wrote the manuscript; LM, GMR, RM, EF, GD critically revised the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest for the present study.
Ethical approval
The study was approved by the appropriate institutional research ethics committee (“Comitato Etico dell’Area Vasta Emilia Nord”) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Fontana, F., Delsante, M., Vicari, M. et al. Mycophenolate mofetil plus steroids compared to steroids alone in IgA nephropathy: a retrospective study. J Nephrol 36, 297–300 (2023). https://doi.org/10.1007/s40620-023-01578-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-023-01578-z